314746-03-7

Upstream product

• 180340-05-0 4-[([1,1'-biphenyl]-2-carbonyl)amino]-benzoyl chloride 
• 5698-18-0 3,4,5,6-tetrahydro-1H-azepino[4,3,2-cd]indole 
• 6047-62-7 1,3,4,6-tetrahydro-azepino[4,3,2-cd]indol-5-one 
• 168626-74-2 4-[([1,1'-Biphenyl]-2-carbonyl)amino]benzoic Acid 
• 5698-17-9 5-oxo-3,4,5,6-tetrahydro-1H-azepino[4,3,2-cd]indole-4-carboxylic acid 
• 5698-16-8 (4-nitro-indol-3-ylmethyl)-malonic acid diethyl ester 
• 7150-46-1 4-nitrogramine 
• 4769-97-5 4-nitro-1H-indoIe 
• 314746-10-6 (4-nitro-phenyl)-(1,3,4,5-tetrahydro-azepino[4,3,2-cd]indol-6-yl)-methanone 
• 122-04-3 4-nitro-benzoyl chloride 
• 14002-52-9 o-phenylbenzoyl chloride 
• 544694-09-9 (4-amino-phenyl)-(1,3,4,5-tetrahydro-azepino[4,3,2-cd]indol-6-yl)-methanone 

Relevant academic research and scientific papers

Indoloazepines as vasopressin receptor antagonists

The invention is directed to tricyclic indoloazepine compounds useful as vasopressin receptor antagonists, pharmaceutical compositions comprising the compounds of the present invention and methods of treating conditions involving increased vascular resist

Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists

A series of novel 3,4,5,6-tetrahydro-1H-azepino[4,3,2-cd]indoles was synthesized and tested for vasopressin receptor antagonist activity. We identified compounds with high affinity for the human V2 receptor and good selectivity over the human V1a receptor